<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00364182</url>
  </required_header>
  <id_info>
    <org_study_id>3090A1-400</org_study_id>
    <secondary_id>B1821002</secondary_id>
    <nct_id>NCT00364182</nct_id>
  </id_info>
  <brief_title>Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B</brief_title>
  <official_title>A Multicenter, Open-Label Study To Compare On-Demand Treatment With 2 Prophylaxis Regimens of Recombinant Coagulation Factor IX (BeneFIX) Reformulated Drug Product (rFIX-R) In Subjects With Severe Hemophilia B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate BeneFIX infused as prophylaxis regimens, compared with
      BeneFIX administered as an on-demand regimen only. In the trial, subjects will participate in
      4 study periods. The first period is a 16-week on-demand treatment, during which subjects
      will utilize BeneFIX to treat bleeding events episodically only as they occur (i.e.,
      on-demand treatment). At the end of this period, subjects will be randomly assigned to 1 of 2
      BeneFIX prophylaxis regimens: either 100 IU/kg once weekly or 50 IU/kg twice weekly, and
      followed for 16 weeks. At the end of this period, subjects will use on-demand treatment for 8
      weeks. The purpose of this 8-week period is to mitigate the potential carry-over effect of
      the prior prophylaxis regimen on bleeding frequency. Following this 8-week on-demand
      treatment, subjects will cross-over and receive the alternate study prophylactic regimen for
      16 weeks.

      The primary endpoint is annualized number of bleeding episodes, compared between the first
      on-demand period and each of the prophylaxis regimens. A comparison of annualized bleeding
      episodes between the two prophylaxis regimens will also be performed. Subject-reported
      outcomes will also be collected using a patient diary. At 24 and 48 hours following the onset
      of each joint bleeding episode, information on pain, sleep, and work will be collected.
      Additional data on physical functioning will be recorded on the diary at the end of the
      16-week on-demand period, and at the end of each prophylaxis period. Information on safety
      will also be collected.

      Each subject will participate in this study for approximately 59 weeks (15 months), including
      a screening period of up to 3 weeks, an initial 16-week on-demand period, two prophylaxis
      treatment periods of 16 weeks each, separated by an 8-week on-demand treatment period.

      A modified FIX recovery study will be performed once during each prophylaxis period.

      The study diary will also be used by subjects to collect secondary endpoints. These
      endpoints, which are subject-reported outcomes, will be recorded in the diary at 24 and 48
      hours following the onset of each joint bleeding episode. Additional data on physical
      functioning will be recorded on the diary at the end of the 16-week on-demand period, and at
      the end of each prophylaxis period.

      Patients will be recruited in the United States, Canada, Europe and Russia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized Number of Bleeding Episodes</measure>
    <time_frame>Baseline up to Week 56</time_frame>
    <description>Annualized bleed rate (ABR) or number of bleeds per year derived for each participant for each treatment regimen by using the following formula: ABR = number of bleeds / (days on treatment regimen / 365.25)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of Sleep Measured by Sleep Diary After Hemarthrosis</measure>
    <time_frame>24 and 48 hours post-bleed</time_frame>
    <description>For each bleeding event, a diary was filled out that night and the subsequent night. Questions included: How long do you think you slept last night? Reported as average duration of sleep during study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Sleep Measured by Sleep Diary After Hemarthrosis</measure>
    <time_frame>24 and 48 hours post-bleed</time_frame>
    <description>For each bleeding event, a diary was filled out that night and the subsequent night. Questions included: How would you describe the quality of your sleep last night? 1=Very Good, 2=Good, 3=Fair, 4=Poor, 5=Very Poor. Reported as quality of sleep during study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Pain After Hemarthrosis</measure>
    <time_frame>24 and 48 hours post-bleed</time_frame>
    <description>For each bleeding event, a diary was filled out that night and the subsequent night and included a Brief Pain Inventory (BPI): self-reported scale that measured severity of pain experienced over the past 24 hours. Questions included How much pain right now? 0 (no pain) to 10 (pain as severe as you can imagine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Productivity Questionnaire (HRPQ) Score: Hours Lost From Work or School at 24 Hours Post-bleed</measure>
    <time_frame>24 hours post-bleed</time_frame>
    <description>HRPQ: self-reported scale that measured for each bleed event, hours lost from work, school and housework because of hemophilia and its treatments. Mean and standard deviations calculated from measured values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRPQ Score: Hours Lost From Work or School at 48 Hours Post-bleed</measure>
    <time_frame>48 hours post-bleed</time_frame>
    <description>HRPQ: self-reported scale that measured for each bleed event, hours lost from work, school and housework because of hemophilia and its treatments. Mean and standard deviations calculated from measured values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-Item Short-Form Health Survey (SF-36): Physical Functioning Domain</measure>
    <time_frame>Weeks 16, 32, and 56</time_frame>
    <description>SF-36: standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The physical functioning domain score was an average of the individual physical functioning question scores across all time points, which was scaled 0-100 (100=highest level of functioning).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Coagulation Factor IX (BeneFIX)</intervention_name>
    <description>100 IU/kg once weekly then crossover to 50 IU/kg twice weekly</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Coagulation Factor IX (BeneFIX)</intervention_name>
    <description>50 IU/kg twice weekly then crossover to 100 IU/kg once weekly</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented history of moderately severe or severe hemophilia B (FIX:C less than or
             equal to 2%)

          -  Male subjects, aged 6 years to 65 years.

          -  Subjects with a minimum of 12 bleeding episodes, 6 of which must be joint bleeds, in
             the 12 months before screening.

        Exclusion Criteria:

          -  Subjects currently utilizing FIX primary prophylaxis.

          -  Subjects with HIV+ who have a CD4 count less than 200

          -  Subjects with hepatic or renal impairment.

          -  Prothrombin time or International Normalized Ration more than 1.5 times the upper
             limit of normal.

          -  Major surgery or an orthopedic surgical procedure within the past 3 months or is
             planned within the duration of participation in this study.

          -  Past history of, or current FIX inhibitor.

          -  Hypersensitivity to any FIX product or hamster protein.

          -  Exposure to any investigational drug, except for rFIX-R, or device within 30 days of
             providing consent/assent (as appropriate) for this study.

          -  Bleeding disorders other than hemophilia B.

          -  Concurrent inflammatory disease that in the investigator's judgment could confound the
             study results.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-3833</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903-0019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Castelfranco Veneto (TV)</city>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Coppito (AQ)</city>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>011155</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191186</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3090A1-400&amp;StudyName=Study%20Comparing%20On-Demand%20Treatment%20With%20Two%20Prophylaxis%20Regimens%20Of%20BeneFIX%20In%20Patients%20With%20Severe%20Hemophilia%20B</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2006</study_first_submitted>
  <study_first_submitted_qc>August 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <results_first_submitted>July 25, 2011</results_first_submitted>
  <results_first_submitted_qc>July 25, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 23, 2011</results_first_posted>
  <last_update_submitted>August 30, 2011</last_update_submitted>
  <last_update_submitted_qc>August 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophilia B</keyword>
  <keyword>BeneFIX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>3 participants who enrolled in the study were not randomized to either prophylaxis treatment regimen, but participated in the study during the first on demand treatment period</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pre-Randomization</title>
          <description>Participants were enrolled and received BeneFix (recombinant coagulation factor IX) as intravenous (IV) bolus infusion in the first on-demand (OD1) period but were never randomized.</description>
        </group>
        <group group_id="P2">
          <title>BeneFIX OD1, Then 100 IU/kg, Then OD2, Then 50 IU/kg</title>
          <description>BeneFIX (recombinant coagulation factor IX) on-demand for 16 weeks (OD1), followed by 100 international units per kilogram (IU/kg) once per week (QW) for 16 weeks prophylactically, followed by 8 weeks BeneFIX on-demand (OD2), followed by 50 IU/kg twice weekly (BW) for 16 weeks prophylactically. Dosage form: IV bolus infusion.</description>
        </group>
        <group group_id="P3">
          <title>BeneFIX OD1 Then 50 IU/kg, Then OD2, Then 100 IU/kg</title>
          <description>BeneFIX (recombinant coagulation factor IX) on-demand for 16 weeks (OD1), followed by 50 IU/kg BW for 16 weeks prophylactically, followed by 8 weeks BeneFIX on-demand (OD2), followed by 100 IU/kg QW for 16 weeks prophylactically. Dosage form: IV bolus infusion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Secondary prophylaxis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Third Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Fourth Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pre-Randomization</title>
          <description>Participants were enrolled and received BeneFix (recombinant coagulation factor IX) as intravenous (IV) bolus infusion in the first on-demand (OD1) period but were never randomized.</description>
        </group>
        <group group_id="B2">
          <title>BeneFIX OD1, Then 100 IU/kg, Then OD2, Then 50 IU/kg</title>
          <description>BeneFIX (recombinant coagulation factor IX) on-demand for 16 weeks (OD1), followed by 100 international units per kilogram (IU/kg) once per week (QW) for 16 weeks prophylactically, followed by 8 weeks BeneFIX on-demand (OD2), followed by 50 IU/kg twice weekly (BW) for 16 weeks prophylactically. Dosage form: IV bolus infusion.</description>
        </group>
        <group group_id="B3">
          <title>BeneFIX OD1 Then 50 IU/kg, Then OD2, Then 100 IU/kg</title>
          <description>BeneFIX (recombinant coagulation factor IX) on-demand for 16 weeks (OD1), followed by 50 IU/kg BW for 16 weeks prophylactically, followed by 8 weeks BeneFIX on-demand (OD2), followed by 100 IU/kg QW for 16 weeks prophylactically. Dosage form: IV bolus infusion.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.3" spread="4.5"/>
                    <measurement group_id="B2" value="31.7" spread="13.4"/>
                    <measurement group_id="B3" value="25.1" spread="14.4"/>
                    <measurement group_id="B4" value="27.7" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annualized Number of Bleeding Episodes</title>
        <description>Annualized bleed rate (ABR) or number of bleeds per year derived for each participant for each treatment regimen by using the following formula: ABR = number of bleeds / (days on treatment regimen / 365.25)</description>
        <time_frame>Baseline up to Week 56</time_frame>
        <population>Intention-to-treat (ITT) population: all enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>BeneFIX OD1</title>
            <description>BeneFIX on-demand IV bolus infusion for 16 weeks (first intervention)</description>
          </group>
          <group group_id="O2">
            <title>BeneFIX 100 IU/kg</title>
            <description>BeneFIX 100 IU/kg IV bolus infusion QW for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BeneFIX 50 IU/kg</title>
            <description>BeneFIX 50 IU/kg IV bolus infusion BW for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Number of Bleeding Episodes</title>
          <description>Annualized bleed rate (ABR) or number of bleeds per year derived for each participant for each treatment regimen by using the following formula: ABR = number of bleeds / (days on treatment regimen / 365.25)</description>
          <population>Intention-to-treat (ITT) population: all enrolled participants</population>
          <units>episodes</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1" lower_limit="28.8" upper_limit="41.4"/>
                    <measurement group_id="O2" value="4.6" lower_limit="2.1" upper_limit="7.2"/>
                    <measurement group_id="O3" value="2.6" lower_limit="-0.1" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-values based on a model including terms for treatment regimen, treatment sequence, and the interaction of these terms with repeated measures on participants.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-30.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.5</ci_lower_limit>
            <ci_upper_limit>-24.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-values based on a model including terms for treatment regimen, treatment sequence, and the interaction of these terms with repeated measures on participants.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-32.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.5</ci_lower_limit>
            <ci_upper_limit>-26.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2167</p_value>
            <p_value_desc>P-values based on a model including terms for treatment regimen, treatment sequence, and the interaction of these terms with repeated measures on participants.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>5.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Sleep Measured by Sleep Diary After Hemarthrosis</title>
        <description>For each bleeding event, a diary was filled out that night and the subsequent night. Questions included: How long do you think you slept last night? Reported as average duration of sleep during study.</description>
        <time_frame>24 and 48 hours post-bleed</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>BeneFIX OD1</title>
            <description>BeneFIX on-demand IV bolus infusion for 16 weeks (first intervention)</description>
          </group>
          <group group_id="O2">
            <title>BeneFIX 100 IU/kg</title>
            <description>BeneFIX 100 IU/kg IV bolus infusion QW for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BeneFIX 50 IU/kg</title>
            <description>BeneFIX 50 IU/kg IV bolus infusion BW for 16 weeks</description>
          </group>
          <group group_id="O4">
            <title>BeneFIX OD2</title>
            <description>BeneFIX on-demand IV bolus infusion for 8 weeks (third intervention)</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Sleep Measured by Sleep Diary After Hemarthrosis</title>
          <description>For each bleeding event, a diary was filled out that night and the subsequent night. Questions included: How long do you think you slept last night? Reported as average duration of sleep during study.</description>
          <population>ITT</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hours post-bleed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="2.0"/>
                    <measurement group_id="O2" value="7.3" spread="1.8"/>
                    <measurement group_id="O3" value="7.1" spread="1.6"/>
                    <measurement group_id="O4" value="7.4" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours post-bleed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="1.7"/>
                    <measurement group_id="O2" value="7.8" spread="1.6"/>
                    <measurement group_id="O3" value="7.5" spread="1.4"/>
                    <measurement group_id="O4" value="8.0" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Mean difference in duration of sleep on the first night (24 hours post-bleed) and the second night (48 hours post-bleed).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mean difference in duration of sleep on the first night (24 hours post-bleed) and the second night (48 hours post-bleed).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mean difference in duration of sleep on the first night (24 hours post-bleed) and the second night (48 hours post-bleed).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mean difference in duration of sleep on the first night (24 hours post-bleed) and the second night (48 hours post-bleed).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.093</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Sleep Measured by Sleep Diary After Hemarthrosis</title>
        <description>For each bleeding event, a diary was filled out that night and the subsequent night. Questions included: How would you describe the quality of your sleep last night? 1=Very Good, 2=Good, 3=Fair, 4=Poor, 5=Very Poor. Reported as quality of sleep during study.</description>
        <time_frame>24 and 48 hours post-bleed</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>BeneFIX OD1</title>
            <description>BeneFIX on-demand IV bolus infusion for 16 weeks (first intervention)</description>
          </group>
          <group group_id="O2">
            <title>BeneFIX 100 IU/kg</title>
            <description>BeneFIX 100 IU/kg IV bolus infusion QW for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BeneFIX 50 IU/kg</title>
            <description>BeneFIX 50 IU/kg IV bolus infusion BW for 16 weeks</description>
          </group>
          <group group_id="O4">
            <title>BeneFIX OD2</title>
            <description>BeneFIX on-demand IV bolus infusion for 8 weeks (third intervention)</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Sleep Measured by Sleep Diary After Hemarthrosis</title>
          <description>For each bleeding event, a diary was filled out that night and the subsequent night. Questions included: How would you describe the quality of your sleep last night? 1=Very Good, 2=Good, 3=Fair, 4=Poor, 5=Very Poor. Reported as quality of sleep during study.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hours post-bleed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.9"/>
                    <measurement group_id="O2" value="2.5" spread="0.9"/>
                    <measurement group_id="O3" value="2.3" spread="0.9"/>
                    <measurement group_id="O4" value="2.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours post-bleed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.7"/>
                    <measurement group_id="O2" value="2.1" spread="0.8"/>
                    <measurement group_id="O3" value="2.1" spread="0.7"/>
                    <measurement group_id="O4" value="2.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Mean difference in quality of sleep on the first night (24 hours post-bleed) and the second night (48 hours post-bleed).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mean difference in quality of sleep on the first night (24 hours post-bleed) and the second night (48 hours post-bleed).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mean difference in quality of sleep on the first night (24 hours post-bleed) and the second night (48 hours post-bleed).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mean difference in quality of sleep on the first night (24 hours post-bleed) and the second night (48 hours post-bleed).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>-0.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Pain After Hemarthrosis</title>
        <description>For each bleeding event, a diary was filled out that night and the subsequent night and included a Brief Pain Inventory (BPI): self-reported scale that measured severity of pain experienced over the past 24 hours. Questions included How much pain right now? 0 (no pain) to 10 (pain as severe as you can imagine).</description>
        <time_frame>24 and 48 hours post-bleed</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>BeneFIX OD1</title>
            <description>BeneFIX on-demand IV bolus infusion for 16 weeks (first intervention)</description>
          </group>
          <group group_id="O2">
            <title>BeneFIX 100 IU/kg</title>
            <description>BeneFIX 100 IU/kg IV bolus infusion QW for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BeneFIX 50 IU/kg</title>
            <description>BeneFIX 50 IU/kg IV bolus infusion BW for 16 weeks</description>
          </group>
          <group group_id="O4">
            <title>BeneFIX OD2</title>
            <description>BeneFIX on-demand IV bolus infusion for 8 weeks (third intervention)</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Pain After Hemarthrosis</title>
          <description>For each bleeding event, a diary was filled out that night and the subsequent night and included a Brief Pain Inventory (BPI): self-reported scale that measured severity of pain experienced over the past 24 hours. Questions included How much pain right now? 0 (no pain) to 10 (pain as severe as you can imagine).</description>
          <population>ITT</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hours post-bleed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.1"/>
                    <measurement group_id="O2" value="2.8" spread="2.0"/>
                    <measurement group_id="O3" value="3.1" spread="2.2"/>
                    <measurement group_id="O4" value="3.0" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours post-bleed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.6"/>
                    <measurement group_id="O2" value="1.8" spread="1.2"/>
                    <measurement group_id="O3" value="2.7" spread="1.5"/>
                    <measurement group_id="O4" value="4.1" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-Related Productivity Questionnaire (HRPQ) Score: Hours Lost From Work or School at 24 Hours Post-bleed</title>
        <description>HRPQ: self-reported scale that measured for each bleed event, hours lost from work, school and housework because of hemophilia and its treatments. Mean and standard deviations calculated from measured values.</description>
        <time_frame>24 hours post-bleed</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>BeneFIX OD1</title>
            <description>BeneFIX on-demand IV bolus infusion for 16 weeks (first intervention)</description>
          </group>
          <group group_id="O2">
            <title>BeneFIX 100 IU/kg</title>
            <description>BeneFIX 100 IU/kg IV bolus infusion QW for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BeneFIX 50 IU/kg</title>
            <description>BeneFIX 50 IU/kg IV bolus infusion BW for 16 weeks</description>
          </group>
          <group group_id="O4">
            <title>BeneFIX OD2</title>
            <description>BeneFIX on-demand IV bolus infusion for 8 weeks (third intervention)</description>
          </group>
        </group_list>
        <measure>
          <title>Health-Related Productivity Questionnaire (HRPQ) Score: Hours Lost From Work or School at 24 Hours Post-bleed</title>
          <description>HRPQ: self-reported scale that measured for each bleed event, hours lost from work, school and housework because of hemophilia and its treatments. Mean and standard deviations calculated from measured values.</description>
          <population>ITT</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Work missed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.6"/>
                    <measurement group_id="O2" value="1.2" spread="2.6"/>
                    <measurement group_id="O3" value="0.6" spread="1.9"/>
                    <measurement group_id="O4" value="0.6" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Housework couldn't do</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="2.4"/>
                    <measurement group_id="O2" value="0.3" spread="0.8"/>
                    <measurement group_id="O3" value="0.4" spread="0.7"/>
                    <measurement group_id="O4" value="0.2" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Classwork couldn't do</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.7"/>
                    <measurement group_id="O2" value="0.7" spread="2.2"/>
                    <measurement group_id="O3" value="0.4" spread="1.1"/>
                    <measurement group_id="O4" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HRPQ Score: Hours Lost From Work or School at 48 Hours Post-bleed</title>
        <description>HRPQ: self-reported scale that measured for each bleed event, hours lost from work, school and housework because of hemophilia and its treatments. Mean and standard deviations calculated from measured values.</description>
        <time_frame>48 hours post-bleed</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>BeneFIX OD1</title>
            <description>BeneFIX on-demand IV bolus infusion for 16 weeks (first intervention)</description>
          </group>
          <group group_id="O2">
            <title>BeneFIX 100 IU/kg</title>
            <description>BeneFIX 100 IU/kg IV bolus infusion QW for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BeneFIX 50 IU/kg</title>
            <description>BeneFIX 50 IU/kg IV bolus infusion BW for 16 weeks</description>
          </group>
          <group group_id="O4">
            <title>BeneFIX OD2</title>
            <description>BeneFIX on-demand IV bolus infusion for 8 weeks (third intervention)</description>
          </group>
        </group_list>
        <measure>
          <title>HRPQ Score: Hours Lost From Work or School at 48 Hours Post-bleed</title>
          <description>HRPQ: self-reported scale that measured for each bleed event, hours lost from work, school and housework because of hemophilia and its treatments. Mean and standard deviations calculated from measured values.</description>
          <population>ITT</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Work missed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.0"/>
                    <measurement group_id="O2" value="0.7" spread="2.1"/>
                    <measurement group_id="O3" value="0.1" spread="0.4"/>
                    <measurement group_id="O4" value="0.2" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Housework couldn't do</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.4"/>
                    <measurement group_id="O2" value="0.3" spread="0.7"/>
                    <measurement group_id="O3" value="0.0" spread="0.2"/>
                    <measurement group_id="O4" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Classwork couldn't do</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.2"/>
                    <measurement group_id="O2" value="0.7" spread="2.4"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="1.7" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>36-Item Short-Form Health Survey (SF-36): Physical Functioning Domain</title>
        <description>SF-36: standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The physical functioning domain score was an average of the individual physical functioning question scores across all time points, which was scaled 0-100 (100=highest level of functioning).</description>
        <time_frame>Weeks 16, 32, and 56</time_frame>
        <population>ITT; N=number of participants with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>BeneFIX OD1</title>
            <description>BeneFIX on-demand IV bolus infusion for 16 weeks (first intervention)</description>
          </group>
          <group group_id="O2">
            <title>BeneFIX 100 IU/kg</title>
            <description>BeneFIX 100 IU/kg IV bolus infusion QW for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BeneFIX 50 IU/kg</title>
            <description>BeneFIX 50 IU/kg IV bolus infusion BW for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>36-Item Short-Form Health Survey (SF-36): Physical Functioning Domain</title>
          <description>SF-36: standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The physical functioning domain score was an average of the individual physical functioning question scores across all time points, which was scaled 0-100 (100=highest level of functioning).</description>
          <population>ITT; N=number of participants with evaluable data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" spread="26"/>
                    <measurement group_id="O2" value="66" spread="25"/>
                    <measurement group_id="O3" value="63" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.544</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.2</ci_lower_limit>
            <ci_upper_limit>4.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.592</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.5</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.131</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>8.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>BeneFIX OD1</title>
          <description>BeneFIX in an on-demand IV bolus infusion for 16 weeks (first intervention)</description>
        </group>
        <group group_id="E2">
          <title>BeneFIX 100 IU/kg</title>
          <description>BeneFIX 100 IU/kg IV bolus infusion QW for 16 weeks</description>
        </group>
        <group group_id="E3">
          <title>BeneFIX 50 IU/kg</title>
          <description>BeneFIX 50 IU/kg IV bolus infusion BW for 16 weeks</description>
        </group>
        <group group_id="E4">
          <title>BeneFIX OD2</title>
          <description>BeneFIX on-demand IV bolus infusion for 8 weeks (third intervention)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Although the protocol-defined endpoint was days lost from work or school after hemarthrosis, data was collected and reported in hours.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

